Since 2009, TNBC Foundation has supported the discovery of promising new treatments for triple negative breast cancer patients through a Susan G. Komen Promise Grant. These multi-year multi-million dollar grants seek to answer the most difficult questions in breast cancer. “This type of research is exactly what we’ve been looking for," said Hayley Dinerman, co-founder and Acting Executive Director. “By co-funding a Promise Grant with Susan G. Komen for the Cure, we can be certain that the project chosen will be an important, multi-faceted, multi-institutional triple negative-specific research initiative with real world clinical impact.”
About Triple Negative Breast Cancer
It is now commonly understood that most breast cancers are characterized by the presence of three receptors (proteins found inside or on the surface of breast cells): estrogen, progesterone and HER2. These receptors are not “expressed” in women with triple negative breast cancer – hence the name. Since most treatments available today are aimed at those receptors, TNBC is difficult to treat, and the tumors are often more aggressive. TNBC represents approximately 15 percent of all breast cancer cases.
About Triple Negative Breast Cancer Foundation
Launched in 2006 in honor of Nancy Block-Zenna, a young woman who was diagnosed at age 35 with triple negative breast cancer and died less than three years later, the Triple Negative Breast Cancer Foundation focuses on raising awareness and supporting research to find a cure for the disease. For more information about TNBC or "triple negative" breast cancer, visit http://www.tnbcfoundation.org.
Help us eradicate Triple Negative Breast Cancer by making a donation to support Triple Negative Breast Cancer research. Click here.